Study guide
22.4 EBDVD Revision Strategy & Cross-Topic Review
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
22.4 EBDVD Revision Strategy & Cross-Topic Review
Key Takeaways Explain This Topic AI
The EBDVD pass rule of 55% (22 of 40) in each of the five sessions means revision should leave no session weak, because a high total cannot offset a failed session (UEMS-EBDV).
Each 60-minute, 40-question session allows an average of 90 seconds per question, and the absence of negative marking means no question should be left blank.
The 2026 timetable gave 15-minute breaks after Sessions 1, 2, and 4 and a one-hour break from 12:30 to 13:30 CEST after Session 3 (UEMS-EBDV).
A five-step image routine reads site, primary lesion, configuration, and special investigations (dermoscopy, histology, immunofluorescence) before synthesising the diagnosis.
Cross-topic safety traps include G6PD testing before dapsone, tuberculosis and hepatitis screening before biologics, and avoiding surgical debridement of pyoderma gangrenosum.
Last updated: September 2026
22.4 EBDVD Revision Strategy & Cross-Topic Review
This closing section turns the official examination rules into a revision plan. It then reviews image-reading technique and the cross-topic safety traps that link chapters. Exam facts (timetable, session topics, pass rule) come from the official UEMS-EBDV page and are set out in full in Section 1.1. The revision advice here is study guidance from this guide, not official Board advice.
Plan Revision by Session, Not by Total Score
The EBDVD is non-compensatory : you need 22 of 40 (55%) in each of the five sessions . The practical consequence is to revise so that no session is weak , rather than piling up marks in favourite topics.
Session (official topics) What It Draws On in This Guide Main European Sources to Know
1: General Terminology, Dermatopathology, Epidemiology, Prevention, General Dermatology Lesion morphology, skin biology, dermatopathology, epidemiology and prevention, photobiology, occupational disease, and general dermatology (psoriasis, lichenoid and papulosquamous disease, acne, rosacea, hair, nails, pigment, systemic disease) EADV burden-of-disease data; ESCD patch-testing guidance; EuroGuiDerm psoriasis guideline
2: General Dermatology, Bullous and Autoimmune Dermatoses, Eczema, Allergology Bullous diseases, connective tissue disease and vasculitis, atopic and contact dermatitis, urticaria, type I allergy, drug reactions, pruritus, and dermatoses of pregnancy EADV bullous disease guidelines; EuroGuiDerm AD guideline; EAACI/GA²LEN/EuroGuiDerm/APAAACI urticaria guideline
3: Infectious Diseases, STD/STI, Ano-genital Diseases Bacterial, mycobacterial, parasitic, viral, and fungal infection; syphilis, gonorrhoea, chlamydia, genital ulcers, other genital infections; HIV; sexual health services; anogenital neoplasia and disorders IUSTI European STI guidelines; WHO leprosy guidance
4: Dermato-Oncology, Dermoscopy Keratinocyte carcinoma, melanoma, naevi, other skin tumours, cutaneous lymphoma, dermoscopy, and imaging EADO melanoma, BCC, and cSCC guidelines; WHO-EORTC lymphoma classification; AJCC 8th edition staging
5: Dermatopharmacology, Therapy, Dermato-Surgery, Phlebology, Angiology, Psychosomatics Topical and systemic therapy, biologics, retinoids, phototherapy, prescribing, surgery, lasers, aesthetic procedures, phlebology, angiology, wounds, psychodermatology EuroGuiDerm systemic therapy guidance; European venous guidelines
A 12-Week Revision Outline
Weeks 1–4: one pass through every chapter. Mark each session as strong, adequate, or weak using the practice questions at the end of each section.
Weeks 5–8: a second pass focused on the two weakest sessions. Make one-page summaries of tables that recur across topics: autoantigens, staging systems, drug monitoring, and STI regimens.
Weeks 9–11: timed blocks of 40 questions in 60 minutes, one block per session. Treat any block below about 60% as a warning, since the real pass mark of 55% leaves little margin.
Week 12: light review of numbers you tend to forget (margins, doses, criteria), the official logistics, and the image routine below. Attend the mandatory test meeting.
Pacing on the Day
Each session gives you 60 minutes for 40 questions , an average of 90 seconds per question .
A useful rhythm is a first pass answering clear questions quickly and marking hard image questions, then a second pass for the marked items. Leave nothing blank : there is no negative marking.
The official timetable gives 15-minute breaks after Sessions 1, 2, and 4 and a one-hour break (12:30–13:30) after Session 3. Use breaks to rest, not to re-check earlier answers you can no longer change.
Each session is scored separately, so a hard morning session does not decide the afternoon. Treat every session as a fresh 40-question test.
Clinical Slide and Image Interpretation Protocol
The official examination includes a clinical slide collection, and image-based questions can draw on clinical photographs, dermoscopy, histopathology, immunofluorescence, and microbiology. The Board does not publish what proportion of questions use images. A fixed, five-step routine helps you read any image the same way under time pressure.
The 5-Step Image Interpretation Algorithm
Step 1: Orientation & Anatomical Site Identification:
Determine the exact anatomical location: Is it sun-exposed (malar face, V of neck, dorsal forearms) suggesting photo-induced disorders (polymorphic light eruption, SCLE, porphyria cutanea tarda, solar elastosis) or photoprotected (axillae, buttocks, inguinal folds)?
Is the lesion flexural / intertriginous (inverse psoriasis, erythrasma, candidiasis, Hailey-Hailey disease, hidradenitis suppurativa) or extensor (plaque psoriasis, dermatitis herpetiformis, xanthomas)?
Are mucous membranes involved (oral, genital, conjunctival), directing thinking toward lichen planus, pemphigus vulgaris, mucous membrane pemphigoid, Stevens-Johnson syndrome, or Behçet disease?
Step 2: Primary Lesion Morphology Analysis:
Identify the fundamental primary lesion before considering secondary changes:
Macule / Patch: Flat circumscribed alteration in color (<1 cm vs >=1 cm).
Papule / Plaque: Solid elevated lesion (<1 cm vs >=1 cm).
Nodule: Deep, circumscribed, palpable solid dermal/subcutaneous lesion (>1 cm).
Vesicle / Bulla: Fluid-filled circumscribed blister (<1 cm vs >=1 cm).
Wheal: Transient erythematous, edematous dermal swelling with rapid resolution.
Pustule: Circumscribed epidermal collection of purulent exudate.
Step 3: Configuration & Distribution Patterns:
Linear: Suggests external trauma/contact (phytophotodermatitis, toxic contact dermatitis), Koebner phenomenon (psoriasis, lichen planus, vitiligo), or mosaicism along lines of Blaschko (incontinentia pigmenti, linear epidermal nevus, linear morphea).
Annular / Polycyclic: Centrifugal expansion with active borders: tinea corporis, subacute cutaneous lupus erythematosus (SCLE), erythema annulare centrifugum, granuloma annulare, urticaria.
Targetoid (Iris) Lesions: Concentric three-zone architecture (central dusky/necrotic zone, surrounding pale edematous ring, outer erythematous halo): pathognomonic for erythema multiforme .
Reticular / Livedoid: Net-like vascular branching: livedo reticularis (vasospastic), livedo racemosa (organic arteriolar occlusive disease e.g. Sneddon syndrome, antiphospholipid syndrome), livedoid vasculopathy.
Dermatomal / Herpetiform: Grouped umbilicated vesicles on an erythematous base following a dermatome (herpes zoster) or grouped excoriated vesicles on extensor sites (dermatitis herpetiformis).
Step 4: Special Modalities Integration (Dermoscopy, Histopathology, DIF):
Dermoscopy: Examine architectural symmetry, pigment networks (atypical/broadened in melanoma vs delicate in naevi), vascular patterns (arborizing telangiectasias in basal cell carcinoma; dotted/glomerular vessels in psoriasis or clear cell acanthoma; hairpin vessels with white halos in keratoacanthoma/SCC; crown vessels in sebaceous hyperplasia; blue-white veil and chrysalis structures in melanoma).
Histopathology:
Epidermal reaction pattern: Hyperkeratosis with parakeratosis and absent granular layer (psoriasiform); spongiotic intraepidermal edema (eczematous); interface dermatitis with vacuolar degeneration (lupus, dermatomyositis) or dense band-like lichenoid infiltrate (lichen planus); acantholytic intraepidermal suprabasal splitting (pemphigus vulgaris).
Dermal infiltrate composition: Neutrophils in dermal papillae tips (dermatitis herpetiformis); dense eosinophils (bullous pemphigoid, Wells syndrome); palisading granulomas around necrobiotic collagen (granuloma annulare, necrobiosis lipoidica); non-caseating sarcoidal naked granulomas (sarcoidosis).
Direct Immunofluorescence (DIF):
Intraepidermal intercellular ("chicken-wire" or net-like) IgG and C3: Pemphigus vulgaris (anti-desmoglein 3/1) and pemphigus foliaceus (anti-desmoglein 1).
Continuous linear deposition of IgG and/or C3 along the dermo-epidermal junction (BMZ): Bullous pemphigoid (anti-BP180 / BP230).
Granular IgA deposition exclusively in the dermal papillae tips: Dermatitis herpetiformis (anti-epidermal transglutaminase).
Granular continuous or interrupted IgG, IgM, IgA, and C3 along the BMZ on sun-exposed and sun-protected skin: Lupus Band Test in systemic lupus erythematosus.
Step 5: Clinical Synthesis:
Combine the clinical, dermoscopic, histological, and immunological findings into one diagnosis. Then answer the actual question asked (next investigation, first-line treatment, or complication), using the European guideline position where one exists.
Cross-Topic Safety Traps
These traps cross chapter boundaries. Each one is taught in detail in its own section and gathered here for revision.
Trap 1: Drug-Induced SCLE Misidentified as Plaque Psoriasis
The Trap: A patient develops widespread scaly, erythematous annular or polycyclic plaques on the upper back and chest shortly after initiating a new systemic drug (e.g., terbinafine, hydrochlorothiazide, calcium channel blockers, or anti-TNF biologics). The extensive scaling leads candidates to mistakenly diagnose psoriasis or tinea incognito.
The Key Point: Histopathology of SCLE shows interface vacuolar dermatitis , basal layer liquefaction, necrotic keratinocytes (apoptotic Civatte bodies), and dermal mucin, with epidermal atrophy—the complete opposite of the regular acanthosis, elongated rete ridges, and absent granular layer of psoriasis. Testing reveals circulating anti-Ro/SSA antibodies in >80% to 90% of cases.
Trap 2: Pemphigoid Nodularis Mistaken for Prurigo Nodularis
The Trap: An elderly patient has multiple intensely itchy, excoriated, hyperkeratotic nodules on the limbs, labelled chronic prurigo nodularis, which do not respond to potent topical steroids.
The Key Point: Bullous pemphigoid can present without blisters, including as a prurigo-like eruption ( pemphigoid nodularis ). In an elderly patient with refractory prurigo, take a perilesional biopsy for direct immunofluorescence and test serum for anti-BP180 and anti-BP230 antibodies. Linear IgG and C3 along the basement membrane zone confirms pemphigoid and changes treatment.
Trap 3: Initiating Dapsone Without Quantitative G6PD Testing
The Trap: A patient with confirmed dermatitis herpetiformis is prescribed oral dapsone without prior laboratory enzyme testing, resulting in acute hemolytic crisis, cyanosis, and hemoglobinuria 72 hours later.
The Key Point: Quantitative glucose-6-phosphate dehydrogenase (G6PD) activity must be verified prior to initiating dapsone. G6PD-deficient red blood cells cannot regenerate NADPH, rendering them vulnerable to catastrophic oxidative hemolysis and severe methemoglobinemia induced by dapsone's hydroxylamine metabolite. Baseline reticulocytes, CBC, and methemoglobin levels must be documented.
Trap 4: Initiating Biologics Without Latent TB and Viral Hepatitis Screening
The Trap: A candidate selects immediate initiation of an anti-TNF (adalimumab, certolizumab) or anti-IL-17 (secukinumab) agent for severe psoriasis without pre-treatment infectious screening.
The Key Point: European guidelines mandate mandatory screening for latent tuberculosis infection (LTBI) via an Interferon-Gamma Release Assay (IGRA / QuantiFERON) or tuberculin skin test, combined with a chest radiograph , prior to administering any biologic or JAK inhibitor. In addition, complete hepatitis B serology (HBsAg, anti-HBc total, anti-HBs) , hepatitis C antibody, and HIV testing are obligatory. TNF-alpha is essential for maintaining tuberculous granuloma integrity; anti-TNF therapy without prior isoniazid prophylaxis triggers fatal disseminated or extrapulmonary tuberculosis reactivation.
Trap 5: Misdiagnosing Early Necrotizing Fasciitis as Simple Cellulitis
The Trap: A patient presents with an erythematous, warm, swollen calf diagnosed as uncomplicated cellulitis and prescribed oral flucloxacillin. Over the next 12 hours, the patient deteriorates into septic shock.
The Key Point: The cardinal early diagnostic sign of necrotizing fasciitis is pain out of proportion to physical findings . Red flags indicating deep fascial necrosis include: skin anesthesia/numbness (due to cutaneous nerve ischemia), hemorrhagic bullae, purpuric/violaceous discoloration, woody induration extending beyond the erythema margin, subcutaneous gas/crepitus, and systemic hypotension. Immediate emergency surgical exploration and fasciotomy are required; waiting for imaging or antibiotic response is fatal.
Trap 6: Sharp Debridement of Pyoderma Gangrenosum
The Trap: A surgeon or dermatologist performs aggressive sharp surgical debridement or wedge excision on an expanding, painful pretibial ulcer with purulent discharge.
The Key Point: Pyoderma gangrenosum exhibits profound pathergy —the induction of massive, sterile neutrophilic tissue destruction in response to minor trauma. Sharp surgical debridement provokes catastrophic, explosive ulcer enlargement. Treatment requires immediate medical immunosuppression (high-dose systemic corticosteroids or cyclosporine), while debridement is strictly contraindicated.
High-Yield Summary Revision Matrix
Disease Entity Classic Clinical Presentation & Demographics Pathognomonic Diagnostic Hallmark Target Antigen / Genetic Defect First-Line European Guideline Therapy
Pemphigus Vulgaris Flaccid intraepidermal bullae, extensive painful oral erosions, positive Nikolsky sign. Intraepidermal acantholysis; intercellular IgG/C3 on DIF ("chicken-wire"). Desmoglein 3 (mucosal-dominant) or Desmoglein 3 + 1 (mucocutaneous). Systemic corticosteroids + Rituximab (anti-CD20).
Bullous Pemphigoid Tense subepidermal bullae on urticarial base, severe pruritus in elderly (>70 years). Subepidermal split; dense eosinophils; linear continuous IgG and C3 along BMZ on DIF. BP180 (type XVII collagen) NC16A domain; BP230 . High-dose topical clobetasol propionate 0.05% whole-body or systemic steroids.
Dermatitis Herpetiformis Intensely pruritic, excoriated grouped vesicles on elbows, knees, buttocks, scalp. Subepidermal blister with neutrophil microabscesses at dermal papillae; granular IgA in papillae on DIF. Epidermal transglutaminase (eTG) ; gut tissue transglutaminase (tTG). Strict lifelong gluten-free diet + oral Dapsone (verify G6PD first).
Porphyria Cutanea Tarda (PCT) Skin fragility, subepidermal vesicles, milia, hypertrichosis on dorsal hands/face; tea-colored urine. Subepidermal blister with festooning of dermal papillae; urine coral-pink fluorescence under Wood's lamp. Deficiency of uroporphyrinogen decarboxylase (UROD) ; triggered by iron, alcohol, HCV. Repeated phlebotomy (to a low-normal ferritin) or low-dose hydroxychloroquine/chloroquine ; stop alcohol and oestrogens and test for HCV and HFE mutations.
Erythema Nodosum Tender, erythematous, warm subcutaneous nodules on anterior lower legs; bilateral, non-ulcerating. Septal panniculitis without vasculitis ; Miescher's radial granulomas. Delayed hypersensitivity triggered by Streptococcus , sarcoidosis, IBD, tuberculosis. Bed rest, NSAIDs, potassium iodide; treat underlying etiology.
Necrotizing Fasciitis Rapidly spreading erythema with pain out of proportion , anesthesia, hemorrhagic bullae, shock. Liquefactive necrosis of deep fascia; dishwater pus; high LRINEC score. Polymicrobial (Type I) or Streptococcus pyogenes GAS (Type II). Immediate emergency surgical fasciotomy + IV meropenem/piperacillin-tazobactam + clindamycin.
- Final Checklist (Official Logistics)
- Before the Examination
Application submitted before the deadline ( 1 April for 2026) and fee received in full before the payment deadline ( 31 May for 2026).
Official Acceptance E-mail received after the payment check.
Test meeting attended 1–2 weeks before the examination; computer and phone prepared using the Orzone preparation instructions.
Remote candidates: approved secure room, room photo sent, signed Consent to Invigilate returned, invigilator confirmed, and no iPad-type device.
On-site candidates: your own computer meeting the requirements, and accommodation in Frankfurt arranged yourself.
On the Day
Passport or ID card ready. Candidates paying the EU/EEA/Swiss rate must show an ID document from one of those countries.
Registration from 08:00 CEST; introduction at 08:50; Session 1 starts at 09:00.
Desk cleared of phones, wallets, notes, books, calculators, and other electronic devices.
No photographs, recordings, or notes of questions; keystrokes are monitored.
After the Examination
Results within 3 weeks ; request your individual score in writing if you want it.
Appeals or a results breakdown: within 1 month of the results.
If unsuccessful: up to two retakes within three years , retaking only the failed sessions at the full fee.